T2 Biosystems Management

Management criteria checks 3/4

T2 Biosystems' CEO is John Sperzel, appointed in Jan 2020, has a tenure of 4.83 years. total yearly compensation is $865.50K, comprised of 66.4% salary and 33.6% bonuses, including company stock and options. directly owns 0.002% of the company’s shares, worth $204.50. The average tenure of the management team and the board of directors is 5.8 years and 7.7 years respectively.

Key information

John Sperzel

Chief executive officer

US$865.5k

Total compensation

CEO salary percentage	66.4%
CEO tenure	4.8yrs
CEO ownership	0.002%
Management average tenure	5.8yrs
Board average tenure	7.7yrs

Recent management updates

Recent updates

T2 Biosystems stock rises ~17% after hours on Baltic region distribution agreement

Sep 22

T2 Biosystems' Survival Riddle

Aug 26

T2 Biosystems Q2 2022 Earnings Preview

Aug 12

T2 Biosystems drops 4% on Q2 guidance and 2022 outlook

Jul 06

CEO Compensation Analysis

How has John Sperzel's remuneration changed compared to T2 Biosystems's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-US$43m
Jun 30 2024	n/a	n/a	-US$48m
Mar 31 2024	n/a	n/a	-US$46m
Dec 31 2023	US$866k	US$575k	-US$50m
Sep 30 2023	n/a	n/a	-US$50m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$64m
Dec 31 2022	US$2m	US$575k	-US$62m
Sep 30 2022	n/a	n/a	-US$64m
Jun 30 2022	n/a	n/a	-US$61m
Mar 31 2022	n/a	n/a	-US$55m
Dec 31 2021	US$4m	US$563k	-US$49m
Sep 30 2021	n/a	n/a	-US$47m
Jun 30 2021	n/a	n/a	-US$44m
Mar 31 2021	n/a	n/a	-US$43m
Dec 31 2020	US$3m	US$491k	-US$47m

Compensation vs Market: John's total compensation ($USD865.50K) is above average for companies of similar size in the US market ($USD649.07K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.

CEO

John Sperzel (61 yo)

4.8yrs

Tenure

US$865,500

Compensation

Mr. John J. Sperzel, III, B.Sc., serves as Chief Executive Officer and Director of T2 Biosystems, Inc. since January 8, 2020 and has been its Chairman since July 23, 2021 and serves as President. Mr. Sperz...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
John Sperzel	President	4.8yrs	US$865.50k	0.0019% $ 204.5
John Sprague	Chief Financial Officer	6.8yrs	US$581.00k	0.00069% $ 72.4
Michael Gibbs	Senior VP	8.8yrs	US$622.60k	0.00066% $ 69.2
Kelley Morgan	Chief People Officer	10.7yrs	no data	no data
Brett Giffin	Chief Commercial Officer	3yrs	no data	0.00037% $ 38.8
Roger Smith	Senior Vice President of Science Research & Development	2.7yrs	no data	no data

5.8yrs

Average Tenure

60yo

Average Age

Experienced Management: TTOO's management team is seasoned and experienced (5.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
John Sperzel	President	4.8yrs	US$865.50k	0.0019% $ 204.5
Robin Toft	Independent Director	4.4yrs	US$60.00k	0.00028% $ 29.4
Seymour E. Liebman	Independent Director	8.2yrs	US$40.00k	0.00041% $ 43.0
John Cumming	Lead Independent Director	10.3yrs	US$96.00k	0.00025% $ 26.2
David Elsbree	Independent Director	10.3yrs	US$60.00k	0.00011% $ 11.5
Eric Rosenberg	Member of Clinical Advisory Board	13.5yrs	no data	no data
Louis Rice	Member of Clinical Advisory Board	13.5yrs	no data	no data
Ninfa Saunders	Independent Director	4.4yrs	US$50.00k	0.00036% $ 37.8
Peter Pappas	Member of Clinical Advisory Board	13.5yrs	no data	no data
Michael Pfaller	Member of Clinical Advisory Board	7.3yrs	US$1.10m	no data
Laura Adams	Independent Director	3.1yrs	US$40.00k	0.00021% $ 22.0
Sean Zhang	Member of Scientific Advisory Board	2.6yrs	no data	no data

7.7yrs

Average Tenure

72.5yo

Average Age

Experienced Board: TTOO's board of directors are considered experienced (7.7 years average tenure).

T2 Biosystems Management

Management criteria checks 3/4

Key information

Recent management updates

T2 Biosystems, Inc., Annual General Meeting, Dec 30, 2024

T2 Biosystems, Inc. Announces the Resignation of Thierry Bernard as Class II Director and All Committees of the Board of Directors

Insufficient new directors

T2 Biosystems, Inc., Annual General Meeting, Sep 12, 2023

High number of new directors

T2 Biosystems, Inc. Announces Resignation of Alec Barclay as Chief Operations Officer, Effective November 30, 2022

Recent updates

T2 Biosystems, Inc., Annual General Meeting, Dec 30, 2024

T2 Biosystems Receives Letter from the Nasdaq Regarding Listing Rule 5550(b)(2)

T2 Biosystems, Inc. to Report Q3, 2024 Results on Nov 14, 2024

T2 Biosystems, Inc. Provides Revenue Guidance for the Fourth Quarter 2024

T2 Biosystems, Inc. Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients

T2 Biosystems, Inc. to Report Q2, 2024 Results on Jul 29, 2024

T2 Biosystems, Inc. has filed a Follow-on Equity Offering in the amount of $14.658742 million.

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

T2 Biosystems, Inc. announced that it expects to receive $8.000002 million in funding

T2 Biosystems, Inc. announced that it expects to receive $8.000002 million in funding

T2 Biosystems, Inc. has withdrawn its Follow-on Equity Offering.

T2 Biosystems, Inc. to Report Q1, 2024 Results on May 06, 2024

T2 Biosystems, Inc. has filed a Follow-on Equity Offering.

T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates

T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement

T2 Biosystems Announces Agreement with CRG for Conversion of Term Loan into Equity to Regain Compliance

T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel

T2 Biosystems, Inc. to Report Q4, 2023 Results on Feb 15, 2024

T2 Biosystems Announces Participation in NIH-Funded Antibacterial Resistance Leadership Group (Arlg) Pilot Study for Pneumonia Patients

T2 Biosystems, Inc. Announces the Resignation of Thierry Bernard as Class II Director and All Committees of the Board of Directors

The Nasdaq Listing Qualifications Staff Issues Delist Determination to T2 Biosystems

The Nasdaq Listing Qualifications Staff Issues Delist Determination to T2 Biosystems

T2 Biosystems, Inc. announced delayed 10-Q filing

Insufficient new directors

T2 Biosystems, Inc. Highlights New Clinical Data Presented At IDWeek 2023 Conference

Consensus revenue estimates decrease by 21%, EPS upgraded

T2 Biosystems Provides Nasdaq Compliance Update

T2 Biosystems, Inc. to Report Q3, 2023 Results on Oct 12, 2023

T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel

Price target increased by 58% to US$0.15

T2 Biosystems, Inc. Updates Revenue Guidance for the Year 2023

T2 Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities Requirement

T2 Biosystems Receives Extension through November 20, 2023 to Comply with Nasdaq's Minimum Bid Price and Market Value of Listed Securities Requirements

T2 Biosystems, Inc., Annual General Meeting, Sep 12, 2023

T2 Biosystems, Inc. to Report Q2, 2023 Results on Aug 07, 2023

T2 Biosystems, Inc. Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test

T2 Biosystems, Inc. Provides Revenue Guidance for the Year 2023

T2 Biosystems, Inc. announced that it has received $0.1 million in funding from CR Group L.P.

T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test

T2 Biosystems Receives Letter from Nasdaq Regarding its Shares Failure to Comply with the Market Value of Listed Securities Required for Continued Listing on The Nasdaq Capital Market

T2 Biosystems, Inc. announced delayed 10-Q filing

Insufficient Growth At T2 Biosystems, Inc. (NASDAQ:TTOO) Hampers Share Price

Full year 2022 earnings: EPS misses analyst expectations

Consensus revenue estimates decrease by 50%, EPS upgraded

T2 Biosystems, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

T2 Biosystems, Inc. has completed a Follow-on Equity Offering.

T2 Biosystems, Inc. Announces Positive Results Upon Completion of U.S. Clinical Evaluation for the T2Biothreat Panel

T2 Biosystems Inc. Advances to the Phase 2 in HHS and the Steven and Alexandra Cohen Foundation's LymeX Diagnostics Prize

Consensus EPS estimates fall by 15%

Price target decreased to US$1.85

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

T2 Biosystems, Inc. Announces Resignation of Alec Barclay as Chief Operations Officer, Effective November 30, 2022

T2 Biosystems Regains Compliance with Nasdaq’s Minimum Bid Price Rule

T2 Biosystems, Inc. to Report Q3, 2022 Results on Nov 10, 2022

T2 Biosystems, Inc. Initiates Studies to Add Acinetobacter Baumannii to the FDA-Cleared T2Bacteria Panel

T2 Biosystems, Inc. Announces Plan to Commercialize A Diagnostic Test for Early Lyme Disease

T2 Biosystems to develop, commercialize diagnostic test for early Lyme disease

T2 Biosystems, Inc. Updates Revenue Outlook for the Full Year of 2022

T2 Biosystems, Inc. Announces BARDA Exercise of Contract Option 3 Valued at $3.7 Million

T2 Biosystems announces BARDA exercise of contract option 3 valued at $3.7M

T2 Biosystems stock rises ~17% after hours on Baltic region distribution agreement

T2 Biosystems' Survival Riddle

T2 Biosystems, Inc., Annual General Meeting, Oct 11, 2022

T2 Biosystems, Inc. announced delayed 10-Q filing

T2 Biosystems Q2 2022 Earnings Preview

T2 Biosystems, Inc to Explore Potential to Develop Rapid Molecular Diagnostic Test for Monkeypox Virus

T2 Biosystems, Inc. to Report Q2, 2022 Results on Aug 15, 2022